Join the Oncology Voice Network. Join for Free
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
Immunotherapies Median survival Mean survival Weibull

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?


Share This Article


Summary

  • The average Restricted Mean Survival Time (RMST) for modern oncology agents approved by the FDA from 2013 to 2017 is 3.6 months, which is lower than the average median Overall Survival (OS) or Progression-Free Survival (PFS) of 4.6 months. When assuming a Weibull distribution post-trial, the average mean OS or PFS increases to 6.1 months.
  • Immuno-oncology agents show significant improvements in mean versus median survival, with an average mean survival of 6.9 months using the Weibull distribution, compared to an average median of 3.2 months. Median survival alone is insufficient to understand efficacy in these cases.
  • Biomarker-driven targeted therapies performed better across all survival measures, with median survival at 5.9 months, RMST at 4.6 months, and mean survival at 7.4 months.
  • VEGF-targeted therapies have poorer outcomes with median survival of 2.1 months, RMST of 2.0 months, and mean survival of 2.2 months.
  • The discrepancy between mean and median survival is most pronounced in immuno-oncology agents due to potential durable survival in a minority of patients. Mean survival captures long-term outcomes better than median survival.
  • Using mean survival as a complementary measure in reporting prospective trials can provide valuable insights, particularly for immuno-oncology agents, and help clinicians and payers understand long-term impacts and make informed decisions.
  • Recent value-based frameworks emphasize the need to understand the true benefit of innovative treatments, focusing on the tail of survival curves and potential durable survival in some patients.
  • The study highlights limitations, including the interpretation of RMST depending on trial cut-off times, uncertainty in survival extrapolation using Weibull distribution, and potential contamination of mean survival measures due to censoring.
  • Incorporating RMST alongside median survival in clinical trial reporting can offer more meaningful information for various stakeholders, although mean measures may be less significant for immuno-oncology agents compared to milestone reporting.
 

Understanding the efficacy of treatments is crucial for patients, physicians, and policymakers. Median survival, the most common measure used in the outcome reporting of oncology clinical trials, is easy to understand; however, it describes only a single time point. The interpretation of the hazard ratio is difficult, and its underlying statistical assumptions are not always met. The objective of this study was to evaluate alternative measures based on the mean benefit of novel oncology treatments.

Click for Source Download PDF version
Immunotherapies, Median survival, Mean survival, Weibull

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Article
Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
OVN Avatar Angus Liu

Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

Article
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
OVN Avatar Yan Ji, Jin Y. Jin, David M. Hyman, Geoffrey Kim and Ajit Suri

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology

Explore OVN